|
Wall Street Grand Report
Company: Echo Therapeutics, Inc. (OTCBB: ECTE)
Current PPS: $2.02
ECTE is our new Bio-tech Play! ECTE has been on a strong uptrend and closed strong at $2.02 which is the first time the stock has ever closed above this price point! In our opinion, the technicals look extremely BULLISH and now that the stock has broken out to a new level we feel there is clear skies ahead for this unique Company.
ECTE is penetrating the multi-BILLION Diabetes market! This Company has a revolutionary, PATENTED, one-of-a-kind diabetes monitoring system that uses a proprietary needle-free platform technology! I don’t know if you know anyone who has diabetes but they will tell you how BIG this first to market product could become. Imagine if your child had diabetes and you had to give a needle to them every single day. I have many friends that have to go through this and it is very hard for them. Now imagine a company that has a patented and proprietary product that can eliminate this process and use a NEEDLE-FREE monitoring system! Well we found the Company that has this revolutionary technology and it’s taking off RIGHT NOW!
 > NOW< 
ECTE is EXPLODING and could become a major acquisition target!
ECTE is a transdermal medical device company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System as a platform technology for transdermal drug delivery!
ECTE believes that the Symphony tCGM System will change the paradigm of invasive, needle-based, pisodic glucose testing in the diabetes consumer and hospital critical care markets to one of continuous, needle-free monitoring.
This is a MULTI-BILLION dollar market!!!
ECTE is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation to allow for transdermal drug delivery of a wide range of FDA-approved products! ECTE believes that the Symphony system is an ideal solution for diabetics and critically ill patients allowing for continuous, pain-free monitoring of glucose levels.
The continuous monitoring will enable more accurate management of diabetes (resulting in healthier outcomes) and higher compliance compared to painful, invasive methods for drawing blood today.
ECTE also believes that its Prelude SkinPrep System will allow many drugs currently delivered by needle injection to be administered without a needle by using Prelude prior to transdermal drug administration.
This alone could add substantial value to ECTE in the short-term!
———————————-
ECTE’s $15 Million Agreement
ECTE has signed a $15 million agreement, giving Ferndale Pharmaceuticals a license to develop, market and sell Prelude for enhanced delivery of Ferndale’s topical lidocaine product, LMX4, in North America and the UK. Echo received $750,000 up front and will receive $750,000 upon FDA approval, as well as $12.5 million in milestones and guaranteed minimum royalty payments. Echo will also receive a double digit royalty on net sales of the product.
ECTE could really start top breakout over the next couple of days so start your research tonight and get ready for a big day tomorrow!
More Updates To Come …
Help Spread the word about Wall Street Grand!
You can call us Toll free at 1888-9-Club Grand (1888-925-8247)
Offices are open Monday – Friday, 9:30 am-4:00 pm EST
|
